Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results - CORVUS PHARMACEUTICALS INC

Explicit Guidance:

• Cash Runway: Cash, cash equivalents, and marketable securities as of September 30, 2026 ($202.9 million) are expected to fund operations through the second quarter of 2028.

Business-Segment Outlook:

• Lead Indications (PTCL & Atopic Dermatitis): Both the Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) trial and the Sierra 1 Phase 2 atopic dermatitis trial are on track to meet current timelines.
• Atopic Dermatitis (Phase 2 Sierra 1):
  • Timeline: Top-line data anticipated in the third quarter of 2027.
  • Next Steps: Assuming successful results, a Phase 3 program targeting a primary endpoint (EZ/IGA score at 12–16 weeks) is projected to potentially commence in 2028.
• Hydradenitis Suppurativa (HS):
  • Timeline: A Phase 1b trial (enrolling up to 25 patients) is expected to report data in the first half of 2027.
  • Future Development: Successful results will enable planning for a definitive, randomized Phase 2 trial without waiting for the entire cohort to complete treatment.
• Asthma:
  • Timeline: Trial initiation is on track for the first quarter of 2027. The design includes an interim analysis to assess futility for specific disease subsets (T2 vs. non-T2).
• Autoimmune Lymphoproliferative Disease (ALPS):
  • IND Transfer: The Investigational New Drug (IND) for ALPS is planned to be transferred from NIAID to Corvus to allow for expansion of treatment centers and inclusion of pediatric patients.
• Partner (Angel Pharmaceuticals):
  • Atopic Dermatitis (China): Preliminary data from Cohort 1 is anticipated in March 2027. Cohort 2 enrollment began in November 2026, with data potentially available in the second half of 2027. A Phase 2 portion with 60–90 additional patients is anticipated depending on Cohorts 1 and 2 results.
  • Asthma: Angel plans to launch asthma trials in 2027.

Market and Competitive Outlook:

• Competitive Positioning (PTCL): Corvus aims to provide the first fully FDA-approved treatment option for relapsed/refractory PTCL, a space where current therapies lack full FDA approval.
• Competitive Positioning (Atopic Dermatitis):
  • Differentiation: Mechanism of action (ITK inhibition) does not overlap with JAK inhibitors or Dupixent (dupilumab); preclinical data suggests no cross-resistance in patients who failed prior biologics or JAK inhibitors.
  • Market Fit: Positioned as a potential upfront first-line systemic therapy or for the expanding pool of patients in the relapse setting who have failed other therapies.
  • Sub-segment Opportunity: Targeting patients with elevated IL-17 (Th17 component), a subset identified in Asian populations that may be difficult to treat with Th2-only therapies.
• Competitive Positioning (HS): Differentiation is based on being an oral therapy in a market dominated by injectable biologics, plus a demonstrated effect on fibrosis (a hallmark of HS) via Th17 modulation.
• Market Expansion (Asthma): Aiming to address the 40% of asthma patients suffering from non-T2 (non-allergic) disease, which is currently underserved by most approved therapies targeting only T2 pathways.

Macro / Industry Outlook:

• Regulatory Strategy: Plans to engage with the FDA to expand the number of treatment centers and lower age eligibility for the ALPS program to include pediatrics.
• Biomarker Utilization: Reliance on specific cytokine thresholds (e.g., Eosinophil count >150 for T2 asthma, IL-17 elevation in AD) to define patient cohorts and assess treatment response.

Strategic Initiatives:

• Pipeline Expansion: Strategically expanding development into new indications (HS, Asthma, ALPS) based on the novel ITK inhibition mechanism to address diseases with limited existing options.
• Global Partnerships: Leveraging Angel Pharmaceuticals for clinical development and data generation in China, specifically for atopic dermatitis and asthma.
• Capacity & Enrollment:
  • Sierra 1: Enrolling ~200 patients with a planned 12-week treatment period and 90-day follow-up.
  • Angel Cohort 2: Enrolling 24 patients with higher dose levels (200mg BID, 400mg QD, or placebo).
  • HS Trial: Ahead of enrollment plan after one month of opening; intensively evaluating skin and blood biomarkers (Th17, Th2, Tregs).

Risks and Headwinds to Outlook:

• Futility Analysis (PTCL): An independent data monitoring committee will conduct a futility analysis in Q1 2027 based on progression-free survival (PFS) events. The study could be terminated if the analysis indicates insufficient efficacy. No safety or efficacy data will be disclosed during this interim analysis to avoid bias, though data may be released if the study is stopped for futility.
• Clinical Trial Variability: While baseline characteristics between US and Chinese cohorts appear similar, there are inherent variabilities between cohorts that could impact data interpretation.
• Dosing Adjustments: Pediatric dosing for the ALPS program may require adjustments based on patient size and the transition from adult-only data.
• External Factors: General risks associated with clinical development, including regulatory delays, enrollment rates, and safety profiles, as outlined in Form 10-Q filings.

Management Tone on the Future:

• Confidence: Management expresses high confidence, describing the pipeline as "positioned to generate significant value" in 2027 and characterizing progress as "on track."
• Strategic Clarity: Emphasis on a unified "through-line" of ITK inhibition across multiple Th2 and Th17-driven diseases, with a "favorable safety profile" serving as a key asset.
• Proactivity: Management is proactive in identifying market gaps (e.g., non-T2 asthma, oral HS therapies) and adjusting trial designs (e.g., accepting patients who failed JAK inhibitors/Dupixent in the AD Phase 2 trial).
• Transparency: Willingness to disclose specific efficacy benchmarks for HS (50–60% for Hiscar 50; ~30% for Hiscar 75) and a clear communication protocol for interim futility analyses.

Miscellaneous:

• 2027 Milestone Calendar:
  • December 2026: Initial ALPS data presentation at ASH.
  • Q1 2027: PTCL Phase 3 futility analysis; Asthma trial initiation.
  • March 2027: Angel atopic dermatitis Cohort 1 data.
  • H1 2027: HS Phase 1b results.
  • Q3 2027: Sierra 1 (Corvus) atopic dermatitis top-line data.
  • H2 2027: Angel atopic dermatitis Cohort 2 data; PTCL Phase 3 top-line data.